Business Context and Reporting Period
This Form 8-K Current Report was filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in request metadata) on November 23, 2009. The filing addresses corporate governance changes, specifically the departure of a director and subsequent committee appointments.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
- Director Resignation: Patrick Brady resigned from the Board of Directors on November 23, 2009.
- Committee Appointments: Following the resignation, the Board appointed Neil Clendeninn to the Audit Committee and Michelle Burris to the Nominating and Governance Committee (serving as chair).
- Board Size: The Board fixed its size at five directors.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is limited to reporting the specific events under Item 5.02 and Item 8.01.
Key Facts for Investor Verification
- Verify the reason for Patrick Brady's resignation from the Board.
- Confirm the qualifications and background of the newly appointed committee members, Neil Clendeninn and Michelle Burris.
- Check subsequent filings to ensure the Board composition remains at five directors as fixed in this report.